Anaqua, Inc. vs Atomwise
Side-by-side comparison
| Anaqua, Inc. | Atomwise | |
|---|---|---|
| Product | AcclaimIP | AtomNet |
| Category | Patent Research | Drug Discovery AI |
| What it does | The fastest, most intuitive, and comprehensive patent search and analytics platform. | Deep-learning virtual screening to find novel small-molecule hits faster |
| Pricing model | — | Partnership / Per Project |
| Free trial | Yes | No |
| Target company size | SMB, Mid-Market, Enterprise | Enterprise, Mid-Market |
| Deployment | SaaS | Cloud/SaaS |
| Integrations | iManage, NetDocuments, Aderant, Legal Tracker, Mitratech, SimpleLegal, T360, PATTSY WAVE | Molecular Databases, Laboratory Systems |
| API available | Yes | — |
| Certifications | ISO 27001, SOC 2 Type 2 | — |
About AcclaimIP
AcclaimIP, an integral part of Anaqua's offerings, is a leading intellectual property analytics and search platform. It provides access to a vast global patent database, comprising over 100 million patents worldwide, making it a crucial tool for prior art search professionals and corporate and legal IP leaders. Designed for speed and intuition, AcclaimIP offers industry-best class searching capab
Use cases: Conducting comprehensive prior art searches for patentability assessments., Gaining competitive intelligence and strategic insights from patent data., Improving overall intellectual property strategy and decision-making., Analyzing patent landscapes and identifying trends through advanced analytics., Enhancing efficiency in patent research and analysis workflows.
About AtomNet
AtomNet is Atomwise’s (now Numerion Labs) structure-based AI platform that predicts protein–small-molecule binding to accelerate early drug discovery. It is used by pharma/biotech R&D teams and academic labs to run virtual high-throughput screening (vHTS) across extremely large, synthesizable chemical libraries and prioritize compounds for synthesis and experimental testing. The business value is
Use cases: Virtual high-throughput screening to identify initial hits for a protein target, Finding novel scaffolds for targets with limited or no known ligands (hard-to-drug targets), Prioritizing compounds for synthesis-on-demand procurement and experimental validation, Supporting partner programs from hit identification through lead optimization and candidate selection, Running multi-target discovery programs within strategic pharma collaborations